Tag: ABBV-399
Phase 2 LUMINOSITY Study Shows Positive Results for Telisotuzumab Vedotin in...
Phase 2 LUMINOSITY Study Shows Positive Results for Telisotuzumab Vedotin in for Patients with Previously Treated Non-Small Cell Lung Cancer
AbbVie and Bristol-Myers Squibb Evaluate Telisotuzumab Vedotin and Nivolumab in c-Met...
A new clinical trial collaboration between AbbVie and Bristol-Myers Squibb Company will evaluate the combination of AbbVie's investigational antibody-drug conjugate telisotuzumab vedotin also known...
What to Expect at the 17th World Conference on Lung Cancer
An estimated 225,000 Americans are expected to be diagnosed with lung cancer this year. Recurrent Small Cell Lung Cancer or accounts for 10%...
Clinical Updates Confirming Advances and Meaningful Benefits for Patients
Earlier this year, during the meetings of the American Association for Cancer Research (AACR), held April 16-20 in New Orleans, LA, and the Protein...
ASCO 2016 Emphasizes Collective Wisdom: The Future of Patient-Centered Care and...
Only a few weeks until the start of the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). This year’s ASCO, taking...
